Display platforms recover sequences that remain genetically encoded, survive the chosen cyclization chemistry, and bind under the selection conditions used. They do not, by themselves, establish enzymatic inhibition, cellular activity, proteolytic stability, or a single bound conformation. This briefing covers four abstracts with provider first-publication dates of 1–7 September 2026, read as of 3 October 2026. It is not a complete review of macrocycle screening, and a retrieval week is not evidence of consensus.
What recent campaigns actually recovered
Three experimental abstracts report display-derived macrocycles. None treats enrichment rank as a functional endpoint.
A genetically encoded, macrocyclization-enabled phage-display library incorporating the cysteine-reactive noncanonical amino acid O2beY was used against Cbl-b, a RING-type E3 ubiquitin ligase described as difficult for conventional small molecules because of shallow, extended protein–protein interfaces. Affinity selection followed by biolayer interferometry identified a macrocyclic peptide binder with Kd = 798 ± 50 nM (Yang et al., 1 September 2026). That value is a post-selection dissociation constant, not an enzymatic or cellular readout.
An mRNA display platform with genetic code reprogramming identified macrocyclic peptide inhibitors of TMPRSS2 that bound the protease active site. The most potent macrocycles showed picomolar binding affinities and selectivity across a panel of 22 trypsin-fold serine proteases. The lead sequence had strong in vitro potency, but proteolytic instability reduced cellular activity. A stability-enhanced analog, T2-MCP-19, bound TMPRSS2 with KD = 80 pM and inhibited uptake of SARS-CoV-2 spike-pseudotyped virus-like particles in Calu-3 lung epithelial cells with nanomolar potency. Several peptides also blocked HKU1 coronavirus spike binding, a separate receptor-function assay (Tombling et al., 1 September 2026).
A sortase-mediated phage-display method (SPLOC) introduced low-reactivity electrophilic handles into displayed peptides, then cyclized them intramolecularly with cysteine. Combined with phage display, the approach yielded cyclic peptide ligands of human IgG1 Fc and TROP2 (Xia et al., 4 September 2026). The abstract does not report dissociation constants, panning statistics, or functional assays for those ligands.
| Campaign (first-publication date) | Encoding | Cyclization chemistry | Target(s) | Demonstrated after selection |
|---|---|---|---|---|
| Yang et al., 1 Sep 2026 | Phage display | Macrocyclization with O2beY | Cbl-b | BLI Kd = 798 ± 50 nM |
| Tombling et al., 1 Sep 2026 | mRNA display, genetic-code reprogramming | Macrocyclic peptides (further chemistry not specified in the abstract) | TMPRSS2 | Picomolar binding; 22-protease selectivity panel; T2-MCP-19 KD = 80 pM; nanomolar Calu-3 VLP-uptake inhibition; HKU1 spike-binding blockade |
| Xia et al., 4 Sep 2026 | Phage display | Sortase ligation of low-reactivity electrophiles, then Cys cyclization | IgG1 Fc, TROP2 | Ligands reported; no affinity or function numbers in the abstract |
Chemistry sets the selectable scaffold; selection does not set function
What a library can encode is limited by cyclization chemistry that must remain compatible with the genetic payload. Xia and co-workers note that genetically encoded cyclic-peptide construction typically relies on bioorthogonal cyclization of phage- or mRNA-displayed peptides, so framework diversity tracks the reaction used. Late-stage cysteine crosslinking is convenient, but enzyme-free cyclization is described as facing trade-offs among reaction kinetics, chemoselectivity, and biocompatibility. Prior sortase platforms used only chloroacetyl groups. This study designed additional low-reactivity electrophilic peptide substrates, tested sortase compatibility, and generated various cyclic frameworks (Xia et al.). That expands accessible topology. On the abstract’s evidence, it does not show that every new electrophile changes which sequences win a given selection.
Selection pressure in the reported work is affinity capture against a protein target. Counter-screens during panning are not described in these abstracts. The TMPRSS2 panel of 22 related proteases is a post-selection characterization of recovered binders, not a documented on-selection counter-panning protocol.
Display also cannot select for properties invisible to the binding experiment. The TMPRSS2 lead’s in vitro potency did not predict cellular activity until proteolytic stability was improved (Tombling et al.). Separately, molecular-dynamics simulations of two related cyclic peptide inhibitors (CP1 and CP2) of Zika virus NS2B/NS3 protease—an illustrative simulation study, not a display campaign—found broad intramolecular distance distributions in water, indicating that key crystallographic contacts were not intrinsically maintained unbound. Upon binding, CP2 adopted a more defined ensemble and preserved a short intramolecular contact, whereas CP1 lost its crystallographic d2 contact. CP2 also showed a more focused interaction network and more favorable MM/PBSA and MM/GBSA binding free-energy estimates (three independent 500 ns simulations per system) (Marinho et al., 7 September 2026). A display hit therefore does not establish that the unbound macrocycle is preorganized into the bound pose.
Read a recovered sequence as a starting ligand, then ask which orthogonal measurement actually exists:
- Binding after selection (BLI or equivalent KD), not enrichment rank
- A functional assay on the intended activity, run separately from panning
- Stability in the matrix of that assay
- Selectivity only where a panel was reported
- Cyclization chemistry as a hard constraint on which scaffolds could have been selected
One remaining question is whether the expanded sortase electrophiles change the sequence landscape recovered against a shared target relative to chloroacetyl-only SPLOC, or only the ring topology of binders that similar phage selections would have found anyway. The 4 September abstract reports substrate compatibility and ligand discovery, not a head-to-head selection comparison.
Explore Further
Browse our research peptide catalog and review third-party lab reports & COAs for published batches.
---
Research use only. The information above is provided for educational and laboratory research purposes only. The compounds discussed are not approved for human or veterinary use, diagnosis, treatment, or the prevention of any disease. Nothing here is medical advice.